Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 1 |
Prophylactic vaccine | 1 |
mRNA vaccine | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator Integrant Pty Ltd [+1] |
Start Date14 Apr 2025 |
Sponsor / Collaborator |
Start Date02 Apr 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
FhHDM-1 | Diabetes Mellitus, Type 1 More | Preclinical |
UTIs mRNA vaccine(Starpharma) | Urinary Tract Infections More | Preclinical |
Anti-MUC1 CAR-T cell/PD-1 knockout engineered T cell therapy (Guangzhou Anjie Biomedical Technology) ( MUC1 ) | Non-Small Cell Lung Cancer More | Pending |
Ant-21 ( miR-21 ) | Pulmonary Disease, Chronic Obstructive More | Pending |